Haleon plc: Board
Changes
6
August 2024: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) today announces
the appointment of two independent Non-Executive
Directors to its Board, Alan Stewart and Nancy Avila.
Alan Stewart is to be appointed as
an independent Non-Executive Director on 1 September 2024 and will
join the Audit & Risk, Environmental & Social
Sustainability, Nominations & Governance, and Remuneration
Committees on appointment. Alan will then succeed Deirdre Mahlan as
the Chair of the Audit & Risk Committee when
Deirdre steps down from the Board on 1 October
2024.
Alan has significant corporate
finance, accounting and international experience from a wide range
of consumer-related industries. He has extensive board and listed
company experience. He is currently a Non-Executive Director on the
boards of Diageo plc, where he chairs the Audit Committee and is a
member of the Remuneration and Nomination Committees, and Burberry
Group plc where he chairs the Audit Committee and is a member of
the Nomination and Remuneration Committees. He was previously
Non-Executive Director and Chair of the Remuneration Committee of
Reckitt Benckiser Group PLC. In his executive career, Alan was
Chief Financial Officer of Tesco PLC from 2014 to 2021. Prior to
joining Tesco, Alan was CFO of Marks & Spencer PLC. He is a
Chartered Accountant. Alan was a founder member of the Accounting 4
Sustainability CFO network and is currently a member of Chapter
Zero.
Nancy Avila is to be appointed as an
independent Non-Executive Director on 1 September 2024 and will
join the Audit & Risk Committee on appointment. Nancy has spent
the majority of her career in technology and business operations in
healthcare, life sciences, industrial, and distribution across
several Fortune 100 companies, these include McKesson Corporation,
where she was Chief Information and Technology Officer, Johnson
Controls Inc., and Abbott Laboratories Inc. Nancy has significant
experience leading business transformations with technology,
developing new digital channels for growth, modernising operations
and addressing regulatory, technology, cyber and financial risk.
Nancy is an independent Director of Comerica Incorporated and a
member of the Enterprise Risk Committee.
Sir
Dave Lewis, Haleon's Chair
commented: "On behalf of the
Board, I would like to welcome Alan and Nancy to Haleon. Alan will
bring a wealth of board, executive and leadership insights and
Nancy will bring valuable technology, business transformation,
digital and cyber experience to support the Board's discussions in
these areas. I would like to thank Deirdre for her considerable
contributions to the Board and for chairing the Audit & Risk
Committee since Haleon's listing in July 2022. We wish her all the
best for the future."
The Company confirms that there is
no further information to be disclosed under the requirements of
UKLR 6.4.8R in relation to Alan Stewart's and Nancy Avila's
appointments.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.